Dapsone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia) and TLV (Sweden) recommended or restricted dapsone, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 18.1 years separate the first record, 22 Jun 2007 at TLV (Sweden), from the most recent, 2025 at PBAC (Australia).
AOTMIT (Poland) changed its position: recommended on 21 Feb 2018, not recommended by 18 Oct 2024.
Coverage is thin among the largest agencies: 6 of the eight highest-volume bodies — HAS (France), SMC (Scotland) and PHARMAC (New Zealand) among them — hold no record for dapsone at all.
The file is active: 4 of 7 records date from 2023 or later.
Against its own class, dapsone is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class D10A average 80%.
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess dapsone, on 22 Jun 2007; PBAC (Australia) did not open a file until 2025 — an unusually long tail of 18.1 years between the earliest and latest system to look at it.
2 of the 4 agencies here assessed dapsone more than once, AOTMIT (Poland) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed dapsone.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Dermatitis herpetiformisLeprosyActinomycotic mycetoma | Recommended | source |
| CONITEC (Brazil) | 15 May 2025 | Tratamento da púrpura trombocitopênica imune refratária, crônica ou dependente de corticosteroide em crianças e adolesce… | not incorporated | source |
| AOTMIT (Poland) | 18 Oct 2024 | Disulone reimbursement recommendation | not recommended | source |
| AOTMIT (Poland) | 15 Apr 2021 | Disulone reimbursement recommendation | recommended | source |
| TLV (Sweden) | 22 Jun 2007 | LFN bifaller ansökan för Dapsone | general subsidy | source |
2 further decisions for dapsone, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- isotretinoin — same ATC class D10A — Anti-acne preparations
- clindamycin — same ATC class D10A — Anti-acne preparations
- erythromycin — same ATC class D10A — Anti-acne preparations
- trastuzumab — also decided by CONITEC in 2025Q2
- satralizumab — also decided by CONITEC in 2025Q2
- bosutinib — also decided by CONITEC in 2025Q2
Coverage: 7 decisions for dapsone from 4 agencies, 2007 to 2025. Data to 7 Sep 2026. ATC class D10A — Anti-acne preparations. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.